Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant-Reference-Cited by-同舟云学术

Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant

Published:2022-09-21 Issue:3 Volume:35 Page:
ISSN:0893-8512
Container-title:Clinical Microbiology Reviews
language:en
Short-container-title:Clin Microbiol Rev

Author:

Zhou Hao¹²^ORCID,Møhlenberg Michelle³⁴,Thakor Jigarji C.⁵,Tuli Hardeep Singh⁶,Wang Pengfei⁷,Assaraf Yehuda G.⁸,Dhama Kuldeep⁵,Jiang Shibo⁹

Affiliation:

1. Department of Microbiology, NYU Grossman School of Medicine, New York, New York, USA

2. College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China

3. Department of Biomedicine, Aarhus University, Aarhus, Denmark

4. Center for Cancer Biology, Department of Oncology, VIB-KU Leuven, Leuven, Belgium

5. Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India

6. Department of Biotechnology, Maharishi Markandeshwar (Deemed University), Mullana, Ambala, Haryana, India

7. State Key Laboratory of Genetic Engineering, Shanghai Institute of Infectious Disease and Biosecurity, School of Life Sciences, Fudan University, Shanghai, China

8. The Fred Wyszkowski Cancer Research Laboratory, Faculty of Biology, Technion Israel Institute of Technology, Haifa, Israel

9. Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, Shanghai, China

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) keeps evolving and mutating into newer variants over time, which gain higher transmissibility, disease severity, and spread in communities at a faster rate, resulting in multiple waves of surge in Coronavirus Disease 2019 (COVID-19) cases. A highly mutated and transmissible SARS-CoV-2 Omicron variant has recently emerged, driving the extremely high peak of infections in almost all continents at an unprecedented speed and scale.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Microbiology (medical),Public Health, Environmental and Occupational Health,General Immunology and Microbiology,Epidemiology

Link

https://journals.asm.org/doi/pdf/10.1128/cmr.00014-22

Reference155 articles.

1. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21

2. Business transformation in an age of turbulence – Lessons learned from COVID-19

3. COVID-19 and business failures: The paradoxes of experience, scale, and scope for theory and practice

4. Socioeconomic correlates of SARS-CoV-2 and influenza H1N1 outbreaks

5. Covid-19: What do we know about omicron sublineages?

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of multiple SARS-CoV-2 variants entry by Lycium barbarum L. polysaccharides through disruption of spike protein-ACE2 interaction;International Journal of Biological Macromolecules;2024-03

2. Development of SARS-CoV-2 entry antivirals;Cell Insight;2024-02

3. Allosteric Signal within the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein Mediated by a Class 3 Monoclonal Antibody Revealed through Molecular Dynamics Simulations and Protein Residue Networks;ACS Omega;2024-01-18

4. High-resolution map of the Fc functions mediated by COVID-19-neutralizing antibodies;Proceedings of the National Academy of Sciences;2024-01-10

5. A Retrospective Study in Patients With Varying Prescription Coverage With Ursodeoxycholic Acid and Association With Incidence of COVID-19 Diagnosis in Primary Care;Microbiology and Infectious Diseases The American Medical Journal;2023-11-16